ASHBURN, Va., Aug. 1 /PRNewswire/ -- Innocoll, Inc. announced its sales and marketing subsidiary, Innocoll Pharmaceuticals Ltd., has recently signed a multi-country distribution agreement with BurnsAdler Pharmaceuticals, Inc., for its CollaRx GENTAMICIN SURGICAL IMPLANT. The countries included in the arrangement are: Mexico, Argentina, Chile, Colombia, and a number of the Caribbean islands.
The product is approved as a drug in Central and South America and is indicated for the treatment and prevention of post-operative acquired infection. Used in combination with standard systemic antibiotic therapy, the product delivers high concentrations of gentamicin locally, with minimal systemic concentrations. It can be used in a wide range of surgery types including orthopedic, cardiac, abdominal, vascular, and general surgery. Innocoll, Inc. acquired the product rights from Essex Chemis AG, an affiliated company of Schering-Plough Corporation and has assumed all sales, marketing and distribution activities for the product.
Dr. Michael Myers, President and CEO of Innocoll, Inc., stated, “This is another significant step as we continue to expand the reach of our lead product and further our objective to establish a global distribution network. Central and South America are important pharmaceutical markets, worth over $16 billion, and forecast to grow to over $20 billion by 2008. With a population of 365 million, and a steady economic growth rate, it will become an increasingly important market for us.”
Denise Carter, President of Innocoll Pharmaceuticals, stated, “We are pleased to announce this multi-country deal with BurnsAdler who are an experienced strategic partner in this region. With their expertise, we look forward to expansion of the product use in Mexico where it is already available, as well as its introduction into the other countries included in the Territory.”
The product was developed using Innocoll’s proprietary collagen-based technology, CollaRx(TM), and has been approved in over 40 countries. It is marketed under the following different trade names (COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R) IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R), CRONOCOL(R)) in Europe, Middle East, Africa and Asia.
About GENTAMICIN SURGICAL IMPLANT
GENTAMICIN SURGICAL IMPLANT is a biodegradable fully resorbable implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin, and is indicated as an adjunct to systemic antibiotic therapy for the treatment and prevention of post-surgical acquired infection in both hard and soft tissues. It is based on Innocoll’s CollaRx(TM) technology, a proprietary collagen-based system which locally delivers a wide variety of drug products, and can be formulated for implantable or topical application as a lyophilized sponge or as a cast film.
About Innocoll, Inc.
Innocoll is a privately held, fully integrated, global, hospital specialty pharmaceutical company specializing in surgical and dermatological products. It develops and markets internationally a range of medical products using its proprietary collagen-based technologies, CollaRx(TM) and LiquiColl(R). For more information, please visit http://www.innocoll.com. For product or pipeline information, please visit http://www.innocoll-pharma.com.
About BurnsAdler Pharmaceuticals, Inc.
BurnsAdler is a specialty pharmaceutical company that in-licenses and promotes products in Europe, South America, Mexico, Canada, Puerto Rico and the Caribbean. BurnsAdler’s portfolio currently includes products targeted for the gastroenterology, cardiovascular, orthopedic, oncology, CNS and critical care markets.
Innocoll, Inc.
CONTACT: Michelle Cox, Marketing Manager of Innocoll Pharmaceuticals, +353(0)90 648 6282, or mcox@innocoll-pharma.com
